NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
NGM Biopharmaceuticals, Inc. announced CEO David J. Woodhouse will participate in a panel on oncology targets at the Cowen 44th Annual Health Care Conference. The event will be webcast live and available for replay on NGM Bio's website.
02/20/2024 - 04:01 PM
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44t h Annual Health Care Conference on Tuesday, March 5th , at 9:10 am ET.
A live webcast of the presentation will be available under the Investors and Media sections of NGM Bio’s website at https://ir.ngmbio.com/events-presentations . A replay of the presentation will be archived on NGM Bio’s site for 30 days following the event.
About NGM Bio
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. NGM Bio’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Visit us at www.ngmbio.com for more information.
David J. Woodhouse will participate in the panel discussion on Tuesday, March 5th, at 9:10 am ET at the Cowen 44th Annual Health Care Conference.
Investors can watch the live webcast of the presentation on NGM Bio's website at https://ir.ngmbio.com/events-presentations.
The replay of the presentation will be archived on NGM Bio's site for 30 days following the event.
Ngm Biopharmaceuticals Inc
NASDAQ:NGM
NGM Rankings
#5406 Ranked by Stock Gains
NGM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Biotechnology, Health Technology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
South San Francisco
About NGM
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
